Axsome Therapeutics Inc
$ 253.77
3.02%
11 Jun - close price
- Market Cap 12,932,612,000 USD
- Current Price $ 253.77
- High / Low $ 257.44 / 247.69
- Stock P/E N/A
- Book Value 1.06
- EPS -3.71
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -3.49 %
- 52 Week High 257.44
- 52 Week Low 96.09
About
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$270.28
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.82 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AXSM
2026-06-11 10:40:25
Jefferies has increased its price target for Axsome Therapeutics (NASDAQ: AXSM) shares to $380 from $275, maintaining a Buy rating, due to strong sales outlook for its drug Auvelity. The firm's analysis, supported by discussions with key opinion leaders, suggests Auvelity's peak sales could exceed $6 billion across major depression and Alzheimer's agitation, with management indicating potential for up to $8 billion. This optimistic valuation also considers Axsome's robust late-stage central nervous system pipeline.
2026-06-11 10:39:40
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. reduced its stake in Axsome Therapeutics ($AXSM) by 14.6% in the fourth quarter, selling 47,483 shares, though it still holds 278,835 shares valued at $50.9 million. Axsome Therapeutics reported Q1 revenue of $191.2 million, up 57.4% year-over-year, but missed earnings expectations with an EPS of -$1.26. Despite insider selling, analysts maintain a "Moderate Buy" consensus rating with an average price target of $251.26 for the biopharmaceutical company.
2026-06-11 07:39:40
Clearbridge Investments LLC reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 19.7% in the fourth quarter, selling 11,341 shares and retaining 46,326 shares valued at $8.46 million. Other institutional investors also adjusted their positions, and insider selling has been observed with directors selling shares to cover tax obligations. Despite recent insider sales and a missed earnings estimate, analysts have given Axsome Therapeutics an average "Moderate Buy" rating with a consensus price target of $251.26.
2026-06-11 02:39:40
Axsome Therapeutics director Mark Coleman sold 643 shares for $160,107 at a weighted average price of $249.00 per share, primarily to cover taxes related to restricted stock unit (RSU) settlement. The transaction was conducted under a 10b5-1 trading plan after the vesting of 1,429 RSUs. Following the sale, Coleman directly holds 30,389 shares and indirectly controls 403,856 shares.
2026-06-11 02:39:40
Axsome Therapeutics director Susan Mahony sold $145,017 worth of company shares in early June to cover taxes related to the vesting of restricted stock units (RSUs). These transactions followed her acquisition of 1,429 shares through RSU settlement, bringing her direct holdings to 829 shares. The stock has seen a 128% return over the past year and is trading near its 52-week high.
2026-06-10 22:39:40
Axsome Therapeutics shareholders approved the election of two Class II directors, ratified Deloitte & Touche LLP as their independent auditor for 2026, and supported the executive compensation plan at their 2026 Annual Meeting. This decision signals shareholder confidence in the company's current governance and financial oversight. While analyst ratings are positive with a $290 price target, TipRanks' AI Analyst, Spark, rates AXSM as Neutral due to weak financial fundamentals despite strong revenue growth.
